Evidence map›Paper›PMID 41113458›Full record

ReviewFrontiers in cell and developmental biology2025

The potential role of miR-155 in the tumorigenesis of cervical cancer.

Xu Chen, Liying Zheng, Xianxu Zeng, Nanying Pan

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xu Chen *Department of Pathology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Liying Zheng *Postgraduate Department, First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi, China.
Xianxu ZengDepartment of Pathology, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Nanying PanDepartment of Obstetrics and Gynecology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer poses a major threat to the health of females and is the leading cause of mortality in females. Despite advancements in treatment, most cervical cancer patients have a poor prognosis due to late diagnosis and resistance to treatment. Investigating microRNAs introduces a new path for developing cancer prevention and treatment. miR-155, one of many microRNAs, plays an essential role in tumor development by regulating gene expression processes, such as transcription, translation, and splicing. In cervical cancer, a number of studies have been conducted to exploring the role and mechanisms of miR-155. Therefore, a comprehensive review summarizing all available findings is necessary to clarify the role of miR-155 in cervical cancer development and progression. This review presents an overview of the state-of-the-art research in miR-155 for cervical cancer, including cell apoptosis, migration, invasion, and drug resistance, and highlights its potential as a biomarker and therapeutic target for cervical cancer treatment and prognosis.

Indexed as

cervical cancerclnicalmechanismprognosistumorigenesis

Identifiers

PMID41113458
PMCPMC12531817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.